LA JOLLA, Calif. — You could easily mistake it for a big CD rack. Inside the lab at the California Institute of Biomedical Research, known as Calibr, sits a stacked array of several dozen plastic ...

In March 2012, the California Institute for Biomedical Research (Calibr), a nonprofit devoted to translating basic science into drug candidates, launched amid much fanfare. Fueling the hype was an ...

CAR-T cell therapies rely on gathering a patient's own T cells, modifying them to specifically target cancer cells, and delivering them back to the patient where they eradicate cancer cells in the ...

NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of ...

California biotech Calibr and research partner AbbVie have clearance to start clinical trials of a new CAR-T technology, involving “switchable” cells that aim to eliminate the life-threatening ...

CLF065, a long-acting, once-weekly GLP-2 receptor agonist, advances in two inflammatory bowel disease indications. The studies aim to bring a regenerative treatment option to patients living with IBD, ...

The partnership is an extension of the collaboration from AbbVie and Scripps Research that was formed in 2019, according to the press release. AbbVie and Calibr announced an expanded strategic ...

Pfizer and the California Institute for Biomedical Research (Calibr), a nonprofit translational research institute, have entered into a global strategic collaboration to develop novel antibody-based ...

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) ...

NORTH CHICAGO, Ill. and LA JOLLA, Calif., June 25, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of ...